Lichtenauer, Michael <br/><br/>
Novel Biomarkers for Heart Disease 

 - Basel, Switzerland  MDPI - Multidisciplinary Digital Publishing Institute  2020 
 - 1 electronic resource (420 p.) 
<br/><br/> Open Access 
<br/><br/> Cardiac biomarkers such as troponins and natiuretic peptides have made a great impact on clinical decision making as well as improving our understanding of molecular mechanisms of different disease conditions. However, the biomarkers that are currently in use do not reflect all the multiple disease pathways that are involved in a broad spectrum of cardiac disease conditions ranging from acute coronary syndrome, to heart failure (and heart failure with preserved ejection fraction, HFpEF), to pulmonary hypertension or arrhythmias. In this Special Issue, we will provide an overview of the current developments in the field of biomarker research, beginning with research on molecular pathways and cellular communication (e.g., microRNA) up to the clinical use of biomarkers. 
<br/><br/><br/>Creative Commons 
<br/><br/><br/>English 
<br/><br/><label>ISBN: </label>books978-3-03943-884-6 9783039438839 9783039438846 
<br/><br/><label>Standard No.: </label>10.3390/books978-3-03943-884-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Medicine
<br/><br/><label>Subjects--Index Terms: </label>diet quality ceramides obesity cardiovascular risk healthy eating index carbohydrate antigen-125 heart failure inflammatory marker older women biomarker cardiometabolic disease epicardial adipose tissue epicardial fat epicardial fat volume microRNA thyroid-stimulating hormone cardiometabolic risks metabolic syndrome hypertension very low-density lipoprotein STIM1 SOCE atrial myopathy atrial fibrillation ejection fraction soluble urokinase-type plasminogen activator receptor (suPAR) growth differentiation factor 15 (GDF-15) heart-type fatty acid-binding protein (H-FABP) soluble suppression of tumorigenicity 2 (sST2) acute myocardial infarction biomarkers catestatin coronary artery disease heart failure decompensation left ventricular ejection fraction troponin NT-proBNP NYHA functional class GDF-15 cardiovascular surgery operative risk muscle wasting sarcopenia renal dysfunction chronic kidney disease aortic disease aneurysm miRNA TGF-β pathway KLF4 synthetic phenotype aortic regurgitation echocardiography magnetic resonance imaging vena contracta area longitudinal strain T1 mapping GDF8 myostatin AMI ceruloplasmin H-FABP heart-type fatty acid-binding protein FABP3 fatty acid-binding protein 3 HF cardiac biomarkers cardiac magnetic resonance imaging left ventricular systolic function magnetic resonance spectroscopy myocardial triglyceride content cell adhesion molecule repeated measurements pregnancy-associated plasma protein-A cohort studies cardiovascular diseases mitochondrial dysfunction circulating cells PBMCS platelets oxidative stress reactive oxygen species (ROS) mitochondrial DNA (mtDNA) herat failure liver-type fatty-acid-binding protein long-term outcomes cardiac intensive care units acute kidney injury myocardial infarction STEMI cardiovascular events cardiovascular death risk stratification sST2 Pentraxin-3 sudden cardiac death ventricular arrhythmia ventricular tachycardia chronic heart failure saliva salivary biomarkers CKD CVD PPCI left ventricular adverse remodelling circulating miRNAs NAFLD Framingham risk score risk prediction secondary prevention primary prevention NAFLD fibrosis score HFpEF HFrEF suPAR n/a